Martínez JÁ, Fernández-Noyola G, Camacho-Castro A, García-Salcido F, Muñoz-Ibarra E, Osornio-Sánchez V, Ahumada-Tamayo S, Mayorga-Gómez E, Garza-Sainz G, Fulda-Graue S, Cantellano-Orozco M, Morales-Montor G, Martínez-Arroyo C, Pacheco-Gahbler C

Language: Spanish
References: 11
Page: 50-55
PDF size: 352.41 Kb.

ABSTRACT

Introduction: Late-onset hypogonadism is the decrease in serum testosterone levels that is part of the aging process in men. Previously known as Androgen Deficiency in the Aging Male (ADAM), it is clinically characterized by alterations in sexual function, decrease in physical strength and muscle mass, mood changes, and impaired cognition.
Objective: To determine serum testosterone levels, as well as hypogonadism frequency, by age group in patients at the Hospital General Dr. Manuel Gea González.
Material and methods: An open, prospective, crosssectional study was carried out to determine serum testosterone values and late-onset hypogonadism frequency in male patients at the Hospital General Dr. Manuel Gea González that were seen within the time frame of May 31 to August 31, 2011. A questionnaire on hypogonadism symptoms was applied and total serum testosterone level was determined.
Results: A total of 200 men with a mean age of 60.1 years (30-80 year range) were studied. Late-onset hypogonadism frequency was 54% and the mean total testosterone level was 3.97 ng/mL (397 ng/dL).
Conclusions: It is reasonable to assume that the age-related decrease in testosterone levels is partially responsible for the symptoms that present with aging.

REFERENCES

1. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-1281.

2. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972;34:730-735.

3. Morales A, Schulman CC, Tostain J, et al. Testosterone deficiency syndrome (TDS) needs to be named appropriately – the importance of accurate terminology. Eur Urol 2006;50:407-409.

4. Bassil N, Morley JE. Late-life onset hypogonadism: a review. Clin Geriatr Med 2010 May;26(2):197-222.

5. Wu FCW, Tajar A, Pye SR, et al. Hypothalamic–pituitary–testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008;93:2737–2745.

6. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.

7. Wang C, Nieschlag E, SwerdLoff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30:1-9.

8. Bassil N. Late-onset hypogonadism. Med Clin North Am 2011;95:507-523.

9. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001;22:718-731.

10. Banks WA, Morley JE, Niehoff ML, et al. Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target 2009;17:91-97.

11. Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fibre hypertrophy and satellite cells in community-dwelling older man. J Clin Endocrinol Metab 2006;91:3024-3033.